Clarity Pharmaceuticals (ASX:CU6) has drawn significant attention and it remains one of the market's most closely followed cancer-imaging and therapy plays. In August 2026, Clarity Pharmaceuticals reported continued progress across its copper-based theranostics pipeline. The company announced completion of recruitment for its AMPLIFY Phase III imaging trial, while recruitment continued in other clinical studies. Its lead SAR-bisPSMA program remains focused on prostate cancer imaging and targeted radiopharmaceutical therapy, with the company highlighting substantial clinical experience across its development programs.

What Could Come Next

Key catalysts include data readouts from the registrational SAR-bisPSMA studies and any regulatory feedback from the US Food and Drug Administration. Progress on Manufacturing and Supply arrangements for its copper isotopes will also be closely followed, given the logistical demands of radiopharmaceutical distribution. Any partnering, licensing or capital-raising activity could likewise move sentiment, as pre-revenue biotechs periodically return to the market to extend their funding runway.

Risks to Watch

The risks are significant and well understood. Clinical Trials can Fail or be delayed, and positive early data does not guarantee registrational success. As a loss-making company, Clarity depends on Capital markets to fund its programs, exposing shareholders to potential dilution. Competition in the radiopharmaceutical space is intensifying, and regulatory timelines are inherently uncertain. These factors help explain why CU6 shares have been volatile and why the stock has featured among recent ASX decliners.

Conclusion

Clarity Pharmaceuticals remains a high-profile but high-risk ASX biotechnology name heading into late 2026. Its advancing Phase III program and growing dataset keep it firmly on investor radars, even as share-price weakness reflects broader caution toward pre-commercial life-sciences stocks. Upcoming trial readouts and regulatory milestones are likely to be the decisive factors for the company's next chapter.